Nephrocare Health Services Limited has formally notified stock exchanges about its upcoming participation in an investor conference, demonstrating the company's commitment to maintaining transparent communication with the investment community.

Conference Details and Schedule

The company has provided comprehensive details about the upcoming investor engagement through an official communication to both BSE Limited and National Stock Exchange of India Limited. The notification, issued under Regulation 30 of SEBI Listing Regulations, outlines the specific arrangements for the investor meetings.

Regulatory Compliance and Information Sharing

The company has emphasized its adherence to regulatory guidelines regarding information disclosure during investor interactions. Company officials have clearly stated that all discussions will be based exclusively on publicly available information, ensuring compliance with securities regulations.

Key compliance aspects include:

• No unpublished price sensitive information (UPSI) will be discussed
• All interactions will follow SEBI Listing Regulations guidelines
• The disclosure is available on the company's official website at www.nephroplus.com
• Potential schedule changes may occur due to exigencies from either the host or company

Corporate Communication Framework

The notification was signed by Kishore Kathri, Company Secretary & Compliance Officer, demonstrating the company's structured approach to corporate governance. The communication was digitally signed and dated March 16, 2026, providing a clear timeline for the advance notice to investors and regulatory authorities.

This investor conference represents part of Nephrocare Health Services Limited's ongoing efforts to engage with analysts and institutional investors, providing them with opportunities to gain insights into the company's operations and strategic direction through formal, regulated channels.

Nephrocare Health Services has received positive coverage from InCred Securities, which has initiated an Add rating on the healthcare company with a target price of ₹613. The brokerage firm's recommendation is based on several key factors that position the company favorably in the healthcare sector.

Market Leadership in Growing Dialysis Segment

InCred Securities highlighted Nephrocare Health Services' strong market position in the dialysis segment, which continues to experience significant growth. The company has established itself as a leader in this specialized healthcare vertical, benefiting from the increasing demand for dialysis services across the country.

Operational Strengths and Growth Potential

The research report emphasized the company's robust operational performance and the substantial growth opportunities available in the dialysis industry. InCred noted that the overall industry growth potential provides a favorable backdrop for Nephrocare's expansion plans and revenue growth.

Asset-Light Business Model

A key highlight of InCred's analysis was Nephrocare's scalable asset-light tie-up model. This business approach allows the company to expand its operations without significant capital investments, thereby supporting healthy margin profiles. The model enables efficient scaling while maintaining cost control.

Risk Considerations

While maintaining a positive outlook, InCred Securities also acknowledged certain execution risks that could potentially impact the company's growth trajectory. These risks are inherent to the healthcare sector and the company's expansion strategy, though they are balanced against the overall positive fundamentals.

The Add rating from InCred Securities reflects confidence in Nephrocare Health Services' ability to capitalize on the growing dialysis market while maintaining operational efficiency through its strategic business model.